BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

297 related articles for article (PubMed ID: 32040684)

  • 1. Contribution and performance of multimodal imaging in the diagnosis and management of cardiac masses.
    Lemasle M; Lavie Badie Y; Cariou E; Fournier P; Porterie J; Rousseau H; Petermann A; Hitzel A; Carrié D; Galinier M; Marcheix B; Lairez O
    Int J Cardiovasc Imaging; 2020 May; 36(5):971-981. PubMed ID: 32040684
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Late Gadolinium Enhancement Cardiac Magnetic Resonance Tissue Characterization for Cancer-Associated Cardiac Masses: Metabolic and Prognostic Manifestations in Relation to Whole-Body Positron Emission Tomography.
    Chan AT; Fox J; Perez Johnston R; Kim J; Brouwer LR; Grizzard J; Kim RJ; Matasar M; Shia J; Moskowitz CS; Steingart R; Weinsaft JW
    J Am Heart Assoc; 2019 May; 8(10):e011709. PubMed ID: 31072171
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessment of combination of contrast-enhanced magnetic resonance imaging and positron emission tomography/computed tomography for evaluation of ovarian masses.
    Tsuboyama T; Tatsumi M; Onishi H; Nakamoto A; Kim T; Hori M; Sakane M; Hori Y; Morii E; Hatazawa J; Tomiyama N
    Invest Radiol; 2014 Aug; 49(8):524-31. PubMed ID: 24637584
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differentiation of malignant and benign cardiac tumors using 18F-FDG PET/CT.
    Rahbar K; Seifarth H; Schäfers M; Stegger L; Hoffmeier A; Spieker T; Tiemann K; Maintz D; Scheld HH; Schober O; Weckesser M
    J Nucl Med; 2012 Jun; 53(6):856-63. PubMed ID: 22577239
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography in the characterization of pancreatic masses: experience from tropics.
    Santhosh S; Mittal BR; Bhasin D; Srinivasan R; Rana S; Das A; Nada R; Bhattacharya A; Gupta R; Kapoor R
    J Gastroenterol Hepatol; 2013 Feb; 28(2):255-61. PubMed ID: 23278193
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of cardiac masses by CMR-strengths and pitfalls: a tertiary center experience.
    Tumma R; Dong W; Wang J; Litt H; Han Y
    Int J Cardiovasc Imaging; 2016 Jun; 32(6):913-20. PubMed ID: 26838354
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multimodality imaging to distinguish between benign and malignant cardiac masses.
    Aghayev A; Cheezum MK; Steigner ML; Mousavi N; Padera R; Barac A; Kwong RY; Di Carli MF; Blankstein R
    J Nucl Cardiol; 2022 Aug; 29(4):1504-1517. PubMed ID: 34476778
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cardiac MRI-based multi-modality imaging in clinical decision-making: Preliminary assessment of a management algorithm for patients with suspected cardiac mass.
    Zhu D; Yin S; Cheng W; Luo Y; Yang D; Lin K; An Q; Sun J; Chen Y
    Int J Cardiol; 2016 Jan; 203():474-81. PubMed ID: 26551882
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Does 18F-FDG PET/MRI reduce the number of indeterminate abdominal incidentalomas compared with 18F-FDG PET/CT?
    Schaarschmidt BM; Grueneisen J; Heusch P; Gomez B; Umutlu L; Ruhlmann V; Rosenbaum-Krumme S; Antoch G; Buchbender C
    Nucl Med Commun; 2015 Jun; 36(6):588-95. PubMed ID: 25759944
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multi-modality Imaging Assessment of Pericardial Masses.
    Zhou W; Srichai MB
    Curr Cardiol Rep; 2017 Apr; 19(4):32. PubMed ID: 28315124
    [TBL] [Abstract][Full Text] [Related]  

  • 11. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of multi-modality functional imaging in differentiation between benign and malignant thyroid
    Shi H; Yuan Z; Yang C; Zhang J; Liu C; Sun J; Ye X
    Clin Transl Oncol; 2019 Nov; 21(11):1561-1567. PubMed ID: 30924093
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of soft-tissue lesions with (18)F-FDG PET/CT: initial results of a prospective trial.
    Leal AL; Etchebehere M; Santos AO; Kalaf G; Pacheco EB; Amstalden EM; Etchebehere EC
    Nucl Med Commun; 2014 Mar; 35(3):252-9. PubMed ID: 24300379
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Integrated 18F-FDG PET/MR imaging in the assessment of cardiac masses: a pilot study.
    Nensa F; Tezgah E; Poeppel TD; Jensen CJ; Schelhorn J; Köhler J; Heusch P; Bruder O; Schlosser T; Nassenstein K
    J Nucl Med; 2015 Feb; 56(2):255-60. PubMed ID: 25552667
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of (18)F-fluorodeoxyglucose positron emission tomography (FDG PET) and cardiac magnetic resonance (CMR) in corticosteroid-naive patients with conduction system disease due to cardiac sarcoidosis.
    Ohira H; Birnie DH; Pena E; Bernick J; Mc Ardle B; Leung E; Wells GA; Yoshinaga K; Tsujino I; Sato T; Manabe O; Oyama-Manabe N; Nishimura M; Tamaki N; Dick A; Dennie C; Klein R; Renaud J; deKemp RA; Ruddy TD; Chow BJW; Davies R; Hessian R; Liu P; Beanlands RSB; Nery PB
    Eur J Nucl Med Mol Imaging; 2016 Feb; 43(2):259-269. PubMed ID: 26359191
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 18-fluorodeoxyglucose positron emission tomography enhances computed tomography diagnosis of malignant intraductal papillary mucinous neoplasms of the pancreas.
    Sperti C; Bissoli S; Pasquali C; Frison L; Liessi G; Chierichetti F; Pedrazzoli S
    Ann Surg; 2007 Dec; 246(6):932-7; discussion 937-9. PubMed ID: 18043094
    [TBL] [Abstract][Full Text] [Related]  

  • 17.
    Marroquín JA; Hernández AC; Pilkington JP; Saviatto A; Tabuenca MJ; Estenoz JM
    Rev Esp Med Nucl Imagen Mol (Engl Ed); 2018; 37(2):110-113. PubMed ID: 28648525
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography in diagnosis and management of pancreatic cancer; comparison with multidetector row computed tomography, magnetic resonance imaging and endoscopic ultrasonography.
    Ergul N; Gundogan C; Tozlu M; Toprak H; Kadıoglu H; Aydin M; Cermik TF
    Rev Esp Med Nucl Imagen Mol; 2014; 33(3):159-64. PubMed ID: 24140024
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 18F-Fluorodeoxyglucose Positron Emission Tomography/Magnetic Resonance in Lymphoma: Comparison With 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography and With the Addition of Magnetic Resonance Diffusion-Weighted Imaging.
    Giraudo C; Raderer M; Karanikas G; Weber M; Kiesewetter B; Dolak W; Simonitsch-Klupp I; Mayerhoefer ME
    Invest Radiol; 2016 Mar; 51(3):163-9. PubMed ID: 26784400
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Accuracy of 18F-FDG PET/CT, Multidetector CT, and MR Imaging in the Diagnosis of Pancreatic Cysts: A Prospective Single-Center Study.
    Kauhanen S; Rinta-Kiikka I; Kemppainen J; Grönroos J; Kajander S; Seppänen M; Alanen K; Gullichsen R; Nuutila P; Ovaska J
    J Nucl Med; 2015 Aug; 56(8):1163-8. PubMed ID: 26045314
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.